{"id":"W2965089489","doi":"10.1016/s1470-2045(19)30171-8","title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"European Research Council; Weill Cornell Medical College; Genentech; Labex Immuno-Oncology; European Research Area Network on Cardiovascular Diseases; PharmaMar; Institut Universitaire de France; Chancellerie des Universités de Paris; Cancéropôle Ile de France; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Fondation pour la recherche juridique; U.S. Department of Defense; European Commission; Institut National de la Santé et de la Recherche Médicale; Bayer HealthCare; Servier; AstraZeneca; Institut National Du Cancer; Fondation Leducq; Agence Nationale de la Recherche; E-Rare; Bristol-Myers Squibb; Direction Générale de l’offre de Soins; Association pour la Recherche sur le Cancer; Seerave Foundation","keywords":"Radioimmunotherapy; Immunotherapy; Medicine; Radiation therapy; Toxicity; Oncology; Internal medicine; Cancer; Immunology; Monoclonal antibody; Antibody","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001195706,0.00102201,0.002370313,0.001585176,0.0001460505,0.001146759,0.001072863,0.001295326,0.003340245],"category_scores_gemma":[0.001734646,0.0003150396,0.0007915474,0.001494501,0.0004493356,0.0009518933,0.0006401858,0.002059818,0.0009931447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008435461,"about_ca_system_score_gemma":0.001011748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00117442,"about_ca_topic_score_gemma":0.00220327,"domain_scores_codex":[0.9995949,0.0001150154,0.00005893791,0.00005246307,0.0001393241,0.00003934473],"domain_scores_gemma":[0.9992976,0.0004796037,0.0001048357,0.00001403141,0.00008403107,0.00001990731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000215102,0.000062757,0.00008662869,0.03826122,0.0002803629,0.00007142028,0.00003369684,0.0006664991,0.001180208,0.003502975,0.01464016,0.9409989],"study_design_scores_gemma":[0.000230386,0.0003268954,0.001299336,0.02045529,0.0009619436,0.0007943569,0.00005103011,0.0002912199,0.001025577,0.004341197,0.9701812,0.00004153409],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006646095,0.999301,0.00006877846,0.0001455673,0.00008662226,0.000004281667,0.000008120287,0.00000294111,0.000316222],"genre_scores_gemma":[0.0007628324,0.9985048,0.0001455958,0.0002385463,0.000105432,0.000007892718,0.00001483511,0.000001195118,0.0002189497],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003340245,"threshold_uncertainty_score":0.0111742,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1501223898713991,"score_gpt":0.4359337749444891,"score_spread":0.28581138507309,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}